Study of the Effect of GM-CSF on Macrophages in Ependymoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 25, 2013

Primary Completion Date

September 21, 2021

Study Completion Date

July 21, 2023

Conditions
Ependymoma, Recurrent ChildhoodEpendymoma
Interventions
DRUG

Granulocyte Macrophage Colony Stimulation Factor

Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.

Trial Locations (2)

32806

Arnold Palmer Hospital for Children, Orlando

80045

Children's Hospital Colorado, Denver

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Children's Hospital Colorado

OTHER

lead

University of Colorado, Denver

OTHER

NCT04408092 - Study of the Effect of GM-CSF on Macrophages in Ependymoma | Biotech Hunter | Biotech Hunter